CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue		$ 121,340	$ 125,444	$ 358,597	$ 318,451
COST OF REVENUE		74,101	71,379	216,794	190,011
Total gross profit		47,239	54,065	141,803	128,440
Operating expenses:
General and administrative		63,839	36,128	158,953	107,085
Research and development		7,409	1,964	13,360	6,129
Sales and marketing		15,704	11,304	46,677	34,757
Total operating expenses		86,952	49,396	218,990	147,971
Loss (income) from operations		(39,713)	4,669	(77,187)	(19,531)
Interest expense, net		1,296	2,458	3,375	4,825
Other income, net		(89)	(11)	(431)	(7,639)
Gain on investment in and loan receivable from non-consolidated affiliate, net		(17,750)	0	(109,260)	0
Loss on extinguishment of debt		0	0	0	1,400
Loss on termination of cash flow hedge		0	0	0	3,506
(Loss) income before taxes		(23,170)	2,222	29,129	(21,623)
Income tax benefit		(2,822)	(335)	(4,283)	(10,378)
Net (loss) income		(20,348)	2,557	33,412	(11,245)
NET (LOSS) INCOME		(20,348)	2,557	33,412	(11,245)
Convertible note accretion, amortization, and interest, net of tax	[1]	0	1,975	0	0
NET (LOSS) INCOME USED IN DILUTED EPS		$ (20,348)	$ 4,532	$ 33,412	$ (11,245)
NET (LOSS) INCOME PER SHARE
Basic (in dollars per share)		$ (0.17)	$ 0.02	$ 0.28	$ (0.10)
Diluted (in dollars per share)		$ (0.17)	$ 0.04	$ 0.28	$ (0.10)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)		122,559	110,461	119,087	107,605
Diluted (in shares)		122,559	119,191	121,356	107,605
Clinical Services
Total revenue		$ 102,227	$ 108,733	$ 300,119	$ 275,599
Total gross profit		42,667	48,126	121,761	117,312
Pharma Services
Total revenue		19,113	16,711	58,478	42,852
Total gross profit		$ 4,572	$ 5,939	$ 20,042	$ 11,128

[1] This adjustment compensates for the effects of the if-converted impact of convertible notes in net income. Since an entity using the if-converted method assumes that a convertible debt instrument was converted into common shares at the beginning of the reporting period, net income is adjusted to reverse any recognized interest expense (including any amortization of discounts).